Navigation Links
Vanda Pharmaceuticals to Present at Natixis Bleichroeder's Hidden Gems Conference
Date:10/3/2007

Presentation Will be Webcast Live and Archived on Company's Web Site

ROCKVILLE, Md., Oct. 3 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders, today announced that Mihael H. Polymeropoulos, M.D., Vanda President and CEO will deliver a corporate presentation on Monday, October 8, 2007, at 3:15 p.m. Eastern Time.

The presentation will take place as part of the Natixis Bleichroeder Hidden Gems Conference at The Carlton, New York. Dr. Polymeropoulos' remarks will be available live on the Vanda Web site, where it also will be archived for 30 days.

To access the presentation, log on to http://www.vandapharma.com and click on the Presentations option in the Investor Relations section. Please connect to the web site several minutes prior to the start of the live presentation to ensure adequate time for any software download that may be necessary.

ABOUT VANDA PHARMACEUTICALS INC.:

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. The company has three product candidates in clinical development. Vanda's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia and bipolar disorder. Vanda's second product candidate, VEC-162, is a compound for the treatment of sleep and mood disorders which is currently in Phase III for insomnia. Vanda's third product candidate, VSF-173, is a compound for the treatment of excessive sleepiness that is in a Phase II clinical trial. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com .


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 24, 2017 , ... ... in Bayside, NY, who have now spent 10 years as clinical instructors for ... University (NYU) College of Dentistry. Through the program, private practitioners receive cutting-edge clinical ...
(Date:5/24/2017)... OH (PRWEB) , ... May 24, 2017 , ... Patients ... in Cortland, OH, can now meet with Dr. Joseph Bedich for a consultation, with ... while simultaneously improving their oral health and functionality. , Dr. Bedich offers ...
(Date:5/24/2017)... ... May 24, 2017 , ... Myers Jackson is well known ... ability to sell luxury homes anywhere on the planet. The luxury home market is ... Hattiesburg to Houston city-scapes. A quick search of “11 Spyglass Hill Auction will enlighten ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... which the endometrial lining of the uterus spreads into the pelvic cavity, ... painful intercourse, painful periods, pelvic pain, or irregular bleeding may have Endometriosis. ...
(Date:5/24/2017)... ... 24, 2017 , ... Accordant Technology, a trusted IT solutions ... an analytics-first approach, layered with machine learning, that provides real-time visibility into the ... cloud to the edge. Through the new partnership, customers get the real-time situational ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... 9, 2017  Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral ... Intellectual Property Office has granted Oramed a patent ... Exenatide". The patent covers Oramed,s invention of an ... is an incretin hormone that stimulates the secretion ...
(Date:5/6/2017)... IRVING, Texas , May 5, 2017   Provista ... 1994 with more than 200,000 customers, today announced Jim ... brings a wealth of executive and business experience to Provista, ... a compounding pharmacy in California . He ... "Jim is a great fit for Provista," says ...
(Date:5/4/2017)... , May 4, 2017  A recent ... Control, Ultraviolet-C light as a means ... SmartUVC,s ability to reduce bioburden on anesthesia workstations. ... reduction on high-touch, complex medical equipment surfaces contaminated ... infections. "This study further validates the ...
Breaking Medicine Technology: